Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | TK1 | P04183 | 5/20 | 0.46 |
| ▸ | DUT | P33316 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046512 | 0.89 | TOP2A (0.47) | TOP2ABCHETK1DUTHDAC1 | |
| SCHEMBL2280328 | 0.89 | BCHE (0.52) | TOP2ABCHETK1 | |
| SCHEMBL12373095 | 0.87 | TOP2A (0.47) | TOP2ABCHETK1DUTHDAC1 | |
| SCHEMBL30848702 | 0.87 | LMNA (0.47) | TOP2ABCHETK1DUTHDAC1 | |
| SCHEMBL3611845 | 0.84 | BCHE (0.55) | BCHETK1 | |
| SCHEMBL25374524 | 0.84 | BCHE (0.50) | TOP2ABCHETK1 | |
| SCHEMBL9126280 | 0.84 | BCHE (0.50) | TOP2ABCHETK1 | |
| SCHEMBL9126273 | 0.84 | BCHE (0.50) | TOP2ABCHETK1 | |
| SCHEMBL30481508 | 0.84 | BCHE (0.50) | TOP2ABCHETK1 | |
| SCHEMBL2011590 | 0.83 | BCHE (0.56) | BCHETK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2021030763-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2019200273-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-3095790-A1 | NUCLEOSIDE-LIPID COMPOUNDS WITH PH-SENSITIVE DIALKYLORTHOESTER CHAINS AND THEIR USE FOR TRANSPORTATION OR VECTORIZATION OF AT LEAST ONE THERAPEUTIC AGENT | UNIVERSITE DE BORDEAUX (FR) | 2016-11-23 | — | — | EP | disclosed |
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | Life Technologies Corporation (US) | 2012-12-06 | — | — | US | disclosed |
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| US-20050214843-A1 | Pyrimidine nucleobases | APPLERA CORPORATION (US) | 2005-09-29 | — | — | US | disclosed |
| US-20050170388-A1 | Pyrimidine nucleobases | APPLERA CORPORATION (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005063787-A2 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | APPLERA CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | PNP, NT5C3B, NUDT1 | TOP2A 255/4885BCHE 1123/4885TK1 342/4885 |
| US-20050170388-A1 | Pyrimidine nucleobases | DPYD, PNP, UMPS | TOP2A 324/4885BCHE 1560/4885TK1 123/4885 |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | PNP, NUDT1, DUT | TOP2A 364/4885BCHE 1664/4885TK1 85/4885 |
| US-20050214843-A1 | Pyrimidine nucleobases | DPYD, PNP, UMPS | TOP2A 324/4885BCHE 1560/4885TK1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.